Mechanisms for redox-regulation of protein kinase C by Susan F. Steinberg
REVIEW
published: 23 June 2015
doi: 10.3389/fphar.2015.00128
Edited by:
Kristina Lorenz,
University of Wuerzburg, Germany
Reviewed by:
Wolfgang F. Graier,
Medical University of Graz, Austria
Gaetano Santulli,
The University of Naples Federico II,
Italy
*Correspondence:
Susan F. Steinberg,
Department of Pharmacology, College
of Physicians and Surgeons,
Columbia University, 630 West 168
Street, New York, NY 10032, USA
sfs1@columbia.edu
Specialty section:
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 01 May 2015
Accepted: 10 June 2015
Published: 23 June 2015
Citation:
Steinberg SF (2015) Mechanisms
for redox-regulation of protein
kinase C.
Front. Pharmacol. 6:128.
doi: 10.3389/fphar.2015.00128
Mechanisms for redox-regulation of
protein kinase C
Susan F. Steinberg*
Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Protein kinase C (PKC) is comprised of a family of signal-regulated enzymes that
play pleiotropic roles in the control of many physiological and pathological responses.
PKC isoforms are traditionally viewed as allosterically activated enzymes that are
recruited to membranes by growth factor receptor-generated lipid cofactors. An inherent
assumption of this conventional model of PKC isoform activation is that PKCs act
exclusively at membrane-delimited substrates and that PKC catalytic activity is an
inherent property of each enzyme that is not altered by the activation process.
This traditional model of PKC activation does not adequately explain the many well-
documented actions of PKC enzymes in mitochondrial, nuclear, and cardiac sarcomeric
(non-sarcolemmal) subcellular compartments. Recent studies address this dilemma by
identifying stimulus-specific differences in the mechanisms for PKC isoform activation
during growth factor activation versus oxidative stress. This review discusses a number
of non-canonical redox-triggered mechanisms that can alter the catalytic properties
and subcellular compartmentation patterns of PKC enzymes. While some redox-
activated mechanisms act at structural determinants that are common to all PKCs,
the redox-dependent mechanism for PKCδ activation requires Src-dependent tyrosine
phosphorylation of a unique phosphorylation motif on this enzyme and is isoform
specific. Since oxidative stress contributes to pathogenesis of a wide range of clinical
disorders, these stimulus-specific differences in the controls and consequences of PKC
activation have important implications for the design and evaluation of PKC-targeted
therapeutics.
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Introduction
Protein kinase C (PKC) comprises a multigene family of related serine/threonine kinases that
mediate a vast number of cellular signaling responses. Cardiomyocytes co-express multiple
PKC isoforms that have been implicated in responses as diverse as cardiac contraction,
cardiac hypertrophy, cardiac ﬁbrosis, ischemia/reperfusion injury, and ischemic preconditioning
(Steinberg, 2008, 2012). PKC isoforms were initially characterized as lipid-sensitive enzymes
that are activated by growth factor receptors that stimulate phospholipase C (PLC; Figure 1).
PLC exists as a family of enzymes with highly conserved catalytic domains that hydrolyzes
phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the calcium-mobilizing second
messenger molecule inositol trisphosphate (IP3) and diacylglycerol (DAG), the lipid cofactor that
allosterically activates PKC. PLC enzymes are subdivided into subclasses based upon the distinctive
structural features in their regulatory domains and their diverse roles in cellular responses. PLCβ
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FIGURE 1 | Receptor-dependent mechanisms that allosterically
activate protein kinase C (PKC). G protein coupled receptors (GPCRs)
and receptor tyrosine kinases (RTKs) activate distinct phospholipase C (PLC)
family enzymes. While the regulatory controls for different PLC family
enzymes differ, these enzymes act in a similar manner to hydrolyze
membrane PIP2 leading to the generation of the calcium-mobilizing second
messenger IP3 and DAG. The redox-sensitive elements in this pathway are
highlighted in yellow (see text).
isoforms are activated by heterotrimeric G protein subunits
(Gαq and Gβγ) and mediate G protein-coupled receptor (GPCR)
responses. In contrast, PLCγ isoforms are recruited to activated
receptor tyrosine kinases (RTKs) where they are activated as a
result of tyrosine phosphorylation by receptor or non-receptor
tyrosine kinases. Since many GPCRs transactivate RTKs, PLC-γ
isoforms have been implicated in both RTK and GPCR signaling
responses.
Conventional models of PKC activation focus exclusively
on the second messenger-driven translocation mechanisms that
deliver these enzymes in an active conformation to their
membrane-delimited substrates. An inherent assumption of
this model is that PKC isoforms act as generic enzymes with
little-to-no substrate speciﬁcity. However, studies over the past
several years have exposed additional mechanisms that alter the
cofactor-requirements and/or catalytic properties of individual
PKCs. Among these, the redox-dependent mechanisms that
regulate PKCs are particularly interesting, since oxidative
stress is a prominent feature of most clinically important
cardiac disorders. While there is ample evidence that increased
levels of reactive oxygen species (ROS) result in adverse
cardiac remodeling and deleterious changes in contractile
performance through direct redox-dependent modiﬁcations of
calcium regulatory proteins and/or structural proteins in the
sarcomere, this review focuses on redox-activated mechanisms
that directly or indirectly inﬂuence signaling by individual
PKCs. These constitute alternative mechanisms to inﬂuence
pump function and/or the pathogenesis of heart failure
that could provide strategies for the development of novel
therapeutics.
The Structural Features that Regulate
Individual Isoforms of PKC
Protein kinase C isoforms are structurally deﬁned by a
highly conserved C-terminal catalytic domain (consisting of
motifs required for ATP/substrate-binding and catalysis) that
is separated by a ﬂexible hinge region from the N-terminal
regulatory domain (Figure 2). Structural features in the
regulatory domain provide the basis to subdivide PKCs into
distinct subfamilies. Conventional PKC isoforms (cPKCs; α,
the alternatively spliced βI/βII isoforms, and γ) contain
two discrete membrane-targeting modules, termed C1, and
C2. The C1 domain is comprised of tandem cysteine-rich
C1A and C1B sequences, with a signature HX12CX2CX13−14
CX2CX4HX2CX7C motif (in which C is cysteine, H is
histidine, and X is any residue). The six cysteine and
two histidine residues in each of the twin C1 domain
structures coordinate zinc ions that stabilize the zinc ﬁnger
structures. C1 domains contain the binding sites for DAG and
tumor-promoting phorbol esters such as phorbol 12-myristate
13-acetate (PMA). The C1 domain lipid-binding sites are
surrounded by a band of hydrophobic residues that form an
extended hydrophobic surface that penetrates the lipid bilayer
and provides a strong driving force to anchor the C1 domains to
the DAG-containing membrane. However, membrane-docking
interactions based upon C1 domain binding to DAG are
not suﬃcient to stabilize full-length cPKCs at membranes.
Rather, cPKC stably associate with membranes as a result
of a second membrane-targeting interaction involving the C2
domain. cPKCs C2 domains of are ∼130 residue eight-stranded
anti-parallel β-sandwich structures with three inter-strand Ca2+-
binding loops (CBLs) responsible for calcium-dependent anionic
phospholipid binding.
Novel PKCs (nPKCs, δ, θ ε, and η) also have twin C1
domains and a C2 domain, although the ordering of nPKC
isoform C1 and C2 domains, along the linear sequence of the
protein, is switched relative to the order in cPKC (Figure 2).
While nPKC C1 domains function as lipid-binding membrane-
targeting modules (much like their counterparts in cPKCs),
nPKCs are maximally activated by agonists that promote DAG
accumulation or by PMA, without a calcium requirement. This
diﬀerence can be attributed to a speciﬁc sequence diﬀerence
between cPKC and nPKC C2 domain. nPKC C2 domains lack
the critical calcium-coordinating aspartic acid residues that
are highly conserved in cPKCs. As a result, the PKCε C2
domain does not bind calcium; it is a membrane-targeting
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FIGURE 2 | Domain structure of cPKC and nPKC family enzymes. The conserved pseudosubstrate motif (shown in orange) N-terminal to the C1 domain
(shown in lavender), the C2 domain (red), and the kinase domain (blue) and the more variable regions (shown in black) are depicted.
module that binds lipids in a calcium-independent manner.
The PKCδ C2 domain is even more distinct from a functional
standpoint, as it does not bind lipids. Rather it is a protein–
protein interaction domain that binds phospho-tyrosine residues
ﬂanked by the consensus sequence (Y/F)-(S/A)-(V/I)-pY-(Q/R)-
X-(Y/F) (Benes et al., 2005). Recent studies indicate that the
PKCθ C2 domain (which shares a high degree of structural
homology to the C2 domain in PKCδ) also functions as a
high aﬃnity phosphotyrosine-binding motif (Stahelin et al.,
2012). The general consensus is that PKCθ is a key signaling
intermediate in immune cells and skeletal muscle, but that it is
not detected in cardiomyocytes (and it has at best only a minor
role in cardiovascular responses).
Regulatory regions of both cPKC and nPKC also contain a
pseudosubstrate motif just N-terminal to their respective C1
domains. The pseudosubstrate motif sequence resembles a PKC
substrate with an alanine substitution at the phosphoacceptor
site (or P-site). For both cPKCs and nPKCs, an intramolecular
autoinhibitory interaction between the regulatory domain
peudosubstrate motif and the kinase domain substrate-
binding pocket maintains a low level of basal catalytic
activity.
Redox-Dependent Mechanisms that
Generate Lipid Cofactors that Activate
PKC
Cells generate ROS through a variety of tightly controlled
metabolic and cellular processes that derive from mitochondrial
respiration and/or growth factor stimulation. High levels of
ROS also are produced during ischemic injury or in response
to many pathologic insults. There is growing evidence that
the subcellular location or the chemical nature of the reactive
species produced in a particular setting determine whether ROS
function as second messengers in signal transduction pathways
or as agents for cellular injury. A major mechanism for ROS-
induced cellular regulation involves chemical modiﬁcation of
reactive thiols in cysteine (or to a lesser extent methionine)
residues in proteins. The reactivity of a particular cysteine
residue is determined by the pKa of its thiol moiety; cysteine
residues adjacent to basic amino acids (Arg or Lys), aromatic
amino acids, or metal centers, have relatively low pKa’s
(<6.5) and tend to be susceptible to oxidation. The resultant
cysteine oxidation can lead to disulﬁde bond formation and
conformational changes that alter protein structure and function.
Since many enzymes have reactive cysteines in their catalytic
centers, oxidation of these cysteine residues leads to enzyme
inactivation. One important class of enzymes with extremely
low pKa active-site catalytic cysteine residues is protein tyrosine
phosphatases (PTPs). Since protein tyrosine phosphorylation
is controlled through the reciprocal actions protein tyrosine
kinases (PTKs) and PTPs – and PTPs are extremely sensitive to
redox-inactivation – this tips the balance in favor of increased
protein tyrosine phosphorylation. This explains PTPs strategic
position as a mediator of oxidant stress-dependent signaling
responses.
Oxidative stress and growth factor receptors activate many
common pathways that culminate in the activation of PKCs. Two
major factors explain the similarity between growth factor and
redox-activated mechanisms. First, many membrane receptors
couple to signaling pathways that culminate in changes in
the expression and/or activity of ROS-generating or anti-
oxidant enzymes. For example, GPCRs (such as angiotensin
II, α1-adrenergic, or endothelin-1 receptors) activate signaling
pathways that lead to increased ROS generation; the receptor-
dependent increase in ROS in turn activates molecular targets
that play critical roles in both physiologic and pathologic growth
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responses (Nakamura et al., 1998; Hirotani et al., 2002; Kuster
et al., 2005; Guo et al., 2009).
Conversely, oxidative stress leads to the activation of certain
components of the canonical GPCR- or RTK-driven signaling
machinery that culminate in the activation of PKCs (Figure 1).
For example, H2O2 treatment increases epithelial growth factor
receptor (EFGR) phosphorylation and oxidation at Cys797, a
critical residue in the active site of the kinase domain (Paulsen
et al., 2012; Truong and Carroll, 2012). Recent studies establish
that the direct H2O2-dependent oxidation of EGFRs at Cys797
increases tyrosine kinase activity (Paulsen et al., 2012). Redox-
activated EGFRs recruit PLCγ, which generates the lipid cofactor
DAG that activates PKCs. Of note, two other EGFR family
members (Her2 and Her4) and nine other receptor or non-
receptor PTKs in the human genome have cysteine residues at
corresponding positions in their kinase domains, suggesting that
cysteine oxidation might constitute a more common mechanism
to activate a selected subset of other tyrosine kinases.
Phospholipase Cγ also is a redox-sensitive protein. PLCγ
enzymes are activated when recruited via their Src homology
(SH) 2 domains to phospho-tyrosine residues on activated
(tyrosine-phosphorylated) RTKs. Receptor-anchored PLCγ is
then tyrosine phosphorylated at critical sites that are essential
to increase PLCγ activity. PLC-β isoforms do not have SH2
domains, are not regulated through tyrosine phosphorylation,
and are not redox-sensitive enzymes. A number of laboratories
have demonstrated that oxidative stress leads to a functionally
important increase in PLCγ tyrosine phosphorylation (Wang
et al., 2001). Studies of mechanism have variably attributed this to
a direct redox-dependent increase in EGFR kinase activity (Wang
et al., 2000), direct redox-dependent or indirect EGFR-dependent
activation of Src kinases, and/or redox-dependent inhibition of
PTPs. Importantly, the redox-activated PLCγ enzyme activates
a cytoprotective pathway that involves PKC (Wang et al.,
2001).
Src-family non-receptor tyrosine kinases (which are
critically regulated through stimulatory and inhibitory tyrosine
phosphorylations) also are activated through a number of redox-
driven mechanisms. Src kinases are structurally characterized
by regulatory SH3 and SH2 domains and a catalytic domain,
that terminates in a C-terminal regulatory sequence containing
an autoinhibitory tyrosine residue; Src kinases are maintained
in a closed inactive conformation with low levels of basal
enzyme activity as a result of an intramolecular autoinhibitory
SH2 domain-C-terminal phospho-tyrosine interaction (Xu
et al., 1999). Src kinases activation requires de-phosphorylation
of the auto-inhibitory phospho-tyrosine (Tyr527 in c-Src),
which releases this autoinhibitory constraint; the enzyme then
autophosphorylates at a positive regulatory site in the activation
loop of the catalytic domain (Tyr418 in c-Src). The Src SH2
domain contains cysteine residues with pKa’s low enough to
be oxidized by physiological levels of ROS. Direct oxidative
modiﬁcation of these SH2 domain cysteine residues leads
to the formation of intra-molecular disulphide bridges that
secondarily disrupt the autoinhibitory Tyr527-SH2 domain
interaction, leading to enzyme activation (Knock and Ward,
2011; MacKay and Knock, 2014). Src also contains a cysteine
residue at a strategic position in its glycine-rich ATP-positioning
loop (G-loop, also known as the phosphate binding P-loop). This
cysteine residue (Cys277 in Src) also has been implicated as a
target for oxidative modiﬁcations that underlie redox-dependent
changes in Src kinase activity (Zhang et al., 2015). Of note, two
other Src family kinases (Yes and Fgr) and four members of the
ﬁbroblast growth factor receptor family have cysteine residues
at corresponding positions in their G loops. This could suggest
that oxidation of a cysteine residue strategically positioned in the
enzyme catalytic center constitutes a mechanism to selectively
regulate only a subset of PTKs. This is in marked contrast to
PTPs, which are inactivated in a more general manner through
direct oxidation of a common active site cysteine. Finally,
direct oxidative modiﬁcation (and inhibition) of the PTP that
dephosphorylate the Src activation loop site also contribute to
redox-activation of Src kinase activity (MacKay and Knock,
2014). Src kinases play an essential role in the redox-dependent
mechanisms that activate PKCδ, which is discussed in the
Section “Direct Redox Modiﬁcations of Cysteine Residues in
PKCs.”
There is limited evidence that free radicals can directly
oxidize membrane phospholipids; PLC-dependent cleavage
of phospholipid hydroperoxides results in the formation of
diacylglycerol hydroperoxide which acts as a very potent
stimulator of PKC in inﬂammatory neutrophils (Kambayashi
et al., 2007). The relevance of oxidized lipid second
messenger molecules at sites of inﬂammation to ischemia-
reperfusion injury in cardiovascular tissues has never been
considered.
Redox-Dependent Mechanisms Involving
Calcium that Can Lead to the Activation
of PKC
Finally, it would be remiss to at least not mention the fact
that excessive ROS can lead to calcium overload by altering
the redox state of key calcium regulatory proteins. While
a detailed discussion of this topic goes beyond the scope
of this review [it is reviewed in Santos et al. (2011) and
Tocchetti et al. (2015)], it is worth noting that several major
proteins involved in excitation-contraction coupling are targets
for functionally important oxidative modiﬁcations. Most studies
have focused on redox modiﬁcations that target the major
calcium regulatory proteins at the sarcoplasmic reticulum (SR),
namely the ryanodine receptor (RyR) Ca2+-release channel or
SR Ca2+-ATPase (SERCA). RyRs are macromolecular complexes
comprised of four RyR protein monomers (each with a molecular
mass of ∼565 kDa) bound to channel stabilizing calstabin
(or FK506 binding protein) subunits and various regulatory
kinases, phosphatases, and phosphodiesterases (Zalk et al.,
2007). Calstabin subunits maintain RyRs in a closed state
that prevents pathologic Ca2+ leak. Any process that triggers
RyR-calstabin dissociation enhances channel open probability
and increases diastolic SR calcium leak (Umanskaya et al.,
2014). Recent studies indicate that RyRs contain many cysteine
residues (almost two dozen per monomer) that are highly
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susceptible to various redox modiﬁcations and that cysteine-
directed oxidative modiﬁcations of RyRs disrupt the calstabin–
RyR interaction. Calstabin-dissociating redox modiﬁcations of
RyRs (due to enhanced ROS generation by calcium-overloaded
dysfunctional mitochondria) have been implicated in age-
related skeletal muscle dysfunction (Andersson et al., 2011),
abnormalities in glucose-induced insulin secretion in pancreatic
β cells (Santulli et al., 2015), and disturbances in diastolic
Ca2+ homeostasis leading to Ca2+ waves and ventricular
extrasystoles in cardiomyocytes (Roussel et al., 2015). SERCA2a
(the major SERCA isoform in cardiomyocytes) also is a target
for oxidation at Cys674 and nitration at Tyr294/Tyr295; these
oxidative modiﬁcations decrease maximal SERCA2 activity
and lead to decreased calcium reuptake during diastolic
relaxation. Finally, calcium overload can result from thiol
oxidization of reactive cysteine residues in the pore-forming
α1C subunit of the voltage-gated L-type Ca channel. This
oxidative modiﬁcation has been linked to increased channel
activity.
Increased intracellular calcium can act as a cofactor to
activate cPKCs through the conventional canonical pathway.
However, increased calcium also would lead to the activation
of calpain, a calcium-dependent cysteine protease that cleaves
the V3 hinge region of PKCα. This proteolytic activation
mechanism liberates a C-terminal constitutively active catalytic
fragment (termed PKMα) that partitions to the nucleus and
acts as an unregulated/mislocalized enzyme to stimulate gene
programs that promote pathological structural and functional
cardiac remodeling (Kang et al., 2010; Zhang et al., 2011).
Of note, while PKCα is the most abundant PKC isoform in
cardiomyocytes – and hence the cardiac actions of PKMα appear
to predominate under conditions of calcium overload – calpain
cleaves other cPKC isoforms and PKCδ (Kishimoto et al., 1989;
Yamakawa et al., 2001). Hence, a calpain-dependent proteolytic
activation mechanism may be a more general mechanism
to activate other PKC isoforms; it may not be speciﬁc for
PKCα.
Direct Redox Modifications of Cysteine
Residues in PKCs
Both the N-terminal regulatory region and the C-terminal
catalytic domains of PKCs contain cysteine residues that are
susceptible to redox modiﬁcations (Figure 3). The cysteine
residues in the regulatory C1 domain are particularly sensitive
to oxidative modiﬁcations that disrupt this structure and
lead to kinase activation. Studies of mechanism suggest that
oxidative modiﬁcation of these cysteine residues (which are
precisely spaced to form a hairpin structure that coordinates zinc
ions) result in the release of zinc atoms and a conformational
change that disrupts the C1 domain lipid-binding pocket
leading to the loss of phorbol ester binding activity (Knapp
and Klann, 2000; Korichneva et al., 2002). However, the
redox-activated enzyme (which does not bind phorbol esters)
is nevertheless a catalytically active enzyme since the C1
domain-targeted oxidative modiﬁcations also disrupt the
FIGURE 3 | Redox-sensitive residues in the C1 domain and kinase
domain common to all PKCs.
adjacent pseudosubstrate domain-mediated autoinhibitory
intramolecular interactions that limits catalytic activity. This
redox-dependent mechanism for PKC activation presumably
underlies previous observations that H2O2 activates PKC
without translocating the enzyme to membranes (Ohmori
et al., 1998). In fact, H2O2 activates PKCs in association with
a reverse redistribution of some PKC family members from
the membrane to the cytosolic fraction in cardiomyocytes and
certain other cell types (Goldberg et al., 1997; Rybin et al.,
2004).
Oxidative modiﬁcations of cysteine residues in the C-terminal
catalytic domain typically require considerably higher
concentrations of H2O2 and result in enzyme inactivation.
While the redox-sensitive residues in PKC kinase domains have
never been localized, the redox-dependent mechanism that
leads to inactivation of the catalytic subunit of protein kinase
A (PKA) may be pertinent, given the high level of sequence
homology between these enzymes. In the case of PKA, Cys199 in
the activation loop is a target for S-glutathionylation (Humphries
et al., 2002). While PKA contains a second redox sensitive
cysteine at position 343 in the C-terminal variable region (that
is not conserved in PKCs), there is evidence that oxidative
modiﬁcations at Cys199 alone can be inactivating (Humphries
et al., 2002, 2005). Two mechanisms have been identiﬁed.
First, while Cys199 is not part of the catalytic mechanism,
it is strategically located in in the P + 1 loop that interacts
with protein substrates. There is some evidence that oxidative
modiﬁcations at this site reduce substrate-binding aﬃnity.
Second, Cys199 oxidation may inhibit enzyme activity through
an indirect mechanism, by facilitating dephosphorylation of
the neighboring Thr197 residue (Humphries et al., 2005). The
PKA activation loop is phosphorylated at Thr197 during
enzyme maturation. Thr197 phosphorylation is a stable
‘priming’ post-translational modiﬁcation that is required to
structure the catalytic pocket in an optimal conformation for
catalysis. PKA-Thr197 phosphorylation is highly resistant to
phosphatases under standard experimental conditions. However,
Cys199 oxidation renders the adjacent activation loop Thr197
phosphorylation site susceptible to phosphatases; this underlies
redox-dependent PKA inactivation. Of note, an activation
loop sequence characterized by cysteine residue strategically
located at the +2 position relative to the ‘priming’ threonine
phosphorylation site that is required for optimal catalytic
activity also is a characteristic feature of all PKC isoforms and
many other AGC family kinases (Figure 3). Studies of PKCα
suggest that this highly conserved chemical environment is
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functionally important, since the oxidative state promotes
PKCα activation loop site dephosphorylation (Humphries
et al., 2005). These results suggest that oxidative modiﬁcations
within the activation loop may play a more general role to
promote the dephosphorylation and inactivation of various
PKCs.
Tyrosine Phosphorylation of PKCδ
While translocation to membranes traditionally has been
considered the hallmark of PKC activation (and traditionally has
been used as a surrogate marker of enzyme activation in a cellular
context), this allosteric model for PKC enzyme activation by lipid
cofactors has two major limitations. First, a model that focuses
exclusively on lipid cofactor-mediated translocation events that
deliver the enzyme to membranes assumes that the cellular
actions of PKCs are exclusively membrane-delimited. In fact,
PKC isoforms are recovered in mitochondria and soluble fraction
of cardiomyocytes subjected to various forms of oxidative stress
(Goldberg et al., 1997; Konishi et al., 2001; Juhaszova et al.,
2004); PKCs in this later fraction could underlie the well-
recognized actions of PKCs to regulate cardiac contractility by
phosphorylating sarcomeric proteins in the contractile apparatus
(at a site physically distant from the lipid bilayer). While there
is some evidence that a subset of regulatory proteins associated
with the contractile apparatus bind certain phospholipids (i.e.,
the actin capping protein CapZ interacts with PIP2) studies to
date indicate that these lipid interactions play a structural role to
regulate actin ﬁlament assemble (Russell et al., 2010). There is no
evidence that sarcomeres are the site of phospholipid hydrolysis
or the generation of DAG. Second, the canonical model for PKC
activation views PKC’s catalytic activity as an inherent property
of the enzyme that is not altered by the activation process. This
model does not adequately explain the diverse (and in some
cases opposing) actions of certain PKC. For example, PKCδ
has been implicated in both ischemia/reperfusion injury and
cardioprotection (Mayr et al., 2004; Churchill et al., 2008).
Early studies showing that PKCδ is activated in a stimulus-
speciﬁc manner in various cell types provided the rationale to
consider a role for oxidative stress as an alternate mechanism to
activate PKCδ. Speciﬁcally, studies in cardiomyocytes established
that GPCR agonists drive PKCδ to lipid-membranes membranes
where it phosphorylates membrane-delimited substrates. The
GPCR-dependent pathway does not lead to a detectable
increase in PKCδ tyrosine phosphorylation. In contrast, oxidative
stress releases PKCδ from membranes, activates Src, promotes
PKCδ-Src complex formation, and Src-dependent PKCδ tyrosine
phosphorylation which increases PKCδ’s catalytic activity (Rybin
et al., 2004). Several other Src family kinases (including Fyn,
Lyn) that are expressed by cardiomyocytes can substitute for
Src in the redox-dependet pathway that activates PKCδ (Rybin
et al., 2004). Importantly, the redox-dependent increases in PKCδ
tyrosine phosphorylation and PKCδ activity are detected in both
the soluble and particulate subcellular compartments, suggesting
that tyrosine phosphorylation confers lipid-independent catalytic
activity.
PKCδ contains sites for tyrosine phosphorylation throughout
the structure, including in the highly conserved regulatory and
kinase domains and the intervening more ﬂexible variable hinge
region. Most of these tyrosine residues are unique to the PKCδ
sequence; they are not conserved in other PKC family enzymes.
Early studies from the Nishizuka laboratory implicated tyrosine
phosphorylation as a mechanism to regulate PKCδ catalytic
activity, showing that the tyrosine-phosphorylated enzyme is
a constitutively activate enzyme that no longer requires DAG
as a cofactor to phosphorylate substrates (Konishi et al., 1997,
2001). It is worth noting that while the initial study from
this group focused on phosphorylations at tyrosine residues
in the regulatory domain (Tyr52 and Tyr187) and a series
of tyrosine residues in the kinase domain [Tyr451, Tyr469,
Tyr512, Tyr523 (Konishi et al., 1997)], the subsequent study
concluded that a Src family kinase (in this case Lck) driven
phosphorylation at Tyr311 (in the more variable ﬂexible hinge
region of the enzyme) mediates the H2O2-dependent increase in
PKCδ activity (Konishi et al., 2001). Note: Tyr311 in rodent PKCδ
corresponds to Tyr313 in human PKCδ; the remainder of this
review uses nomenclature based upon the rodent PKCδ sequence.
PKCδ-Tyr311 phosphorylation was subsequently implicated in
several other PKCδ-dependent cellular responses (Lu et al., 2007;
Nakashima et al., 2008). These results provided traction for the
notion that a pathway that relies on tyrosine phosphorylation,
rather than cysteine oxidation, underlies redox control of PKCδ
activity.
Studies from our group combined molecular and biochemical
approaches to implicate tyrosine phosphorylation as a key
mechanism that mediates redox-dependent changes in PKCδ
catalytic activity. In retrospect, our decision to use a rigorous
in vitro kinase assay approach (which combined measurements
of PKCδ autophosphorylation and PKCδ-dependent
phosphorylation of many sites on heterologous substrates)
proved to be essential to expose a novel mechanism for the
control of PKCδ activity. We used troponin complex as substrate
in the in vitro kinase assays since this myoﬁlament protein
complex represents a physiologically important PKCδ substrate
in cardiomyocytes. Troponin complex is comprised of equimolar
amounts of cardiac troponin I (cTnI), cardiac troponin T
(cTnT), and cardiac troponin C. cTnI and cTnT (the “inhibitory”
and ‘tropomyosin-binding’ subunits of the troponin complex)
function to ﬁne-tune calcium-dependent cardiac contractility.
cTnI and cTnT both have several phosphorylation clusters that
exert distinct eﬀects on cardiac contractility. In an initial set of
studies, we showed that PKCδ phosphorylates cTnI at Ser23/Ser24
when allosterically activated by lipid-cofactors; studies in skinned
single cardiomyocytes linked this phosphorylation to an increase
in the cross-bridge cycling rate and a reduction in myoﬁlament
calcium sensitivity (Sumandea et al., 2008). While this action of
the allosterically activated PKCδ enzyme mimics the eﬀects of the
β-adrenergic receptor-PKA pathway, it is detected exclusively in
our somewhat artiﬁcial reductionist model that is designed to
expose mechanism; its physiologic relevance is doubtful, since
the allosterically activated form of PKCδ does not localize the
contractile machinery in cardiomyocytes. Rather, we identiﬁed
a redox-induced Src-dependent change in PKCδ activity that is
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more physiologically relevant. We showed that PKCδ acquires
activity toward an additional site on cTnI (it phosphorylates
cTnI at both Ser23/Ser24 and Thr144) and it also phosphorylates
a number of threonine phosphorylation sites on cTnT during
oxidative stress when the enzyme is Tyr311-phosphorylated by
Src. This change in PKCδ’s enzymology mediates the redox-
dependent decrease in maximum tension and cross-bridge
kinetics (i.e., a functionally distinct and physiologically relevant
mechanism for PKCδ regulation of contractility (Sumandea
et al., 2008)). The additional observation that the Src-dependent
acquisition of cTnI-Thr144 and cTnT-Thr kinase activity is
completely abrogated by a Y311F substitution implicated
Tyr311-phosphorylation as the mechanism underlying the
Src-dependent increase in PKCδ activity (Sumandea et al., 2008).
A mechanism that might explain how a phosphorylation at
Tyr311 (in the hinge region, outside the catalytic core of the
enzyme) might lead to a change in PKCδ’s enzymology is not
obvious. However, we focused on the intriguing observation
that PKCδ contains a phosphotyrosine binding C2 domain
with a consensus binding sequence [(Y/F)-(S/A)-(V/I)-pY-
(Q/R)-X-(Y/F)] that resembles the sequence ﬂanking Tyr311
(Benes et al., 2005). Tyr311 is the only phosphorylation site
in PKCδ ﬂanked by residues that conform to a PKCδ-C2
domain consensus-binding motif (VGI-Y311-QGF). We used a
FRET-based approach to show that PKCδ’s phosphotyrosine-
binding C2 domain interacts with the Tyr311-phosphorylated
V3 region (Figure 4; Gong et al., 2015). We then showed
that this interaction controls PKCδ catalytic activity indirectly,
by regulating PKCδ phosphorylation at a novel regulatory
phosphorylation site at Ser357 (rodent sequence, corresponding
to Ser359 in human PKCδ). Ser357 sits at the tip of the Gly-
rich ATP-positioning loop (G-loop) within the small lobe of
the kinase domain. The G-loop sequence is highly conserved
in most protein kinases and it forms a ﬂexible clamp that
orients the γ-phosphate of ATP for transfer to substrate; localized
changes in the position of this loop inﬂuence the kinetics
of nucleotide binding and catalysis. We showed that PKCδ
displays a high level of S357 phosphorylation in resting cells
and that the redox-induced docking interaction between the C2
domain and the Tyr311-phosphorylated hinge region leads to S357
dephosphorylation.
Mutagenesis studies implicated G-loop dephosphorylation
as a mechanism to regulate two major aspects of PKCδ’s
enzymology (Gong et al., 2015). First, we showed that the
PKCδ-S357A mutant is a constitutively active lipid-independent
enzyme. The observation that a single non-phosphorylatable
S357A substitution in the G loop confers a high level of lipid-
independent catalytic activity provides a mechanism to account
for the cellular actions of PKCδ in cells subjected to oxidative
stress, where PKCδ phosphorylates substrates throughout the cell
(not just on lipid membranes).
Second, we showed that the S357A substitution changes
the enzyme’s substrate speciﬁcity (Gong et al., 2015). In way
of background, most studies that deﬁne enzyme-substrate
speciﬁcity focus on consensus phosphorylation motifs,
residues that are either preferred or deselected at positions
ﬂanking the phosphoacceptor-site (or P-site). The literature
has generally overlooked the fact that PKC isoforms (and
PKA – enzymes typically characterized as Ser/Thr kinases)
show a clear preference for substrates with a P-site Ser
FIGURE 4 | The redox-dependent pathway involving Src that switches
PKCδ from a lipid-dependent Ser kinase to a lipid independent Ser/Thr
kinase. The structural domains that mediate redox-dependent activation of
PKCδ are highlighted in yellow, with the specific phosphorylation sites in the
variable hinge region (Tyr311) and kinase domain (Ser357) that are key for
redox-dependent activation in red (see text).
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residue. In fact, our early studies showed that the allosterically
activated PKCδ enzyme phosphorylates cTnI at Ser23/Ser24,
but it does not phosphorylate Thr phosphorylation sites
on cTnI or cTnT. The observation that the redox-activated
(Tyr311-phosphorylated/Ser357 dephosphorylated) form of PKCδ
acquires activity toward threonine phosphorylation sites on
cTnI and cTnT provided the rationale to test whether G
loop phosphorylation constitutes a mechanism to regulate
PKCδ’s P-site speciﬁcity. By using a series of rigorous
biochemical approaches, we were able to show that the G loop
phosphorylation site – which (according to structural studies
of the related PKA catalytic subunit) occupies a tight space
adjacent to the P-site on substrates – regulates P-site speciﬁcity.
We showed that a non-phosphorylatable S357A substitution
facilitates (and a phosphomimetic S357E substitution completely
abrogates) PKCδ’s Thr kinase activity. Activity toward substrates
with Ser-phosphoacceptor sites is not aﬀected. These results
implicate G loop Ser357 phosphorylation as a novel dynamically
regulated mechanism that controls PKCδ’s P-site speciﬁcity.
It is worth emphasizing that a post-translational modiﬁcation
within the kinase domain that calibrates an enzyme’s P-site
speciﬁcity in a stimulus-speciﬁc manner is unprecedented. It
is tempting to speculate that the stimulus-speciﬁc diﬀerences
in PKCδ phosphorylation proﬁles (that impact on substrate
speciﬁcity) underlie PKCδ’s diverse roles in both the pathogenesis
of ischemia-reperfusion injury and as a mediator of ischemic
preconditioning (Steinberg, 2012). As a technical note, it also
is worth noting that our studies expose an important and
underappreciated caveat related to previous studies that have
characterized PKCδ enzyme activity. Our studies emphasize that
measurements of stimulus-dependent changes in PKCδ kinase
activity are likely to diﬀer, depending on the readout used in the
assay – and particularly, the nature of the substrate (whether the
substrate P-site is a Ser or Thr residue). This may explain some of
the confounding inconsistencies in previous published literature.
Finally, it is worth mentioning that other tyrosine residues
in the regulatory region of PKCδ, that ﬁgure prominently
in the transduction of genotoxic stress responses, can also
become phosphorylated in the setting of oxidative stress
(Adwan et al., 2011). For example, PKCδ phosphorylation at
Tyr64 and Tyr155 (sites in the regulatory domain) leads to a
conformational change that exposes bipartite nuclear localization
signal in the catalytic domain. This results in an interaction
with importin-α, which is key for the nuclear translocation
of full-length PKCδ and various PKCδ-driven proapoptotic
responses. Oxidative stress also undoubtedly increases PKCδ
phosphorylation at other tyrosine residues throughout the
enzyme, but the controls and consequences of other redox-
induced tyrosine phosphorylations (either in a cardiomyocyte
context or with respect to their eﬀects on catalytic activity) have
not been interrogated. This remains fertile ground for future
investigations.
Concluding Remarks
This review summarizes our current understanding of various
redox-activated mechanisms that regulate signaling by PKCs.
While this narrative considers individual mechanisms separately,
PKCs are subject to an elaborate and complex assortment
of redox-driven modiﬁcations in various pathophysiologic
settings. An understanding of the ensemble eﬀects of these
redox-driven events presents both a challenge and an
opportunity for the development of novel PKC-targeted
therapeutics.
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